July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Determining ocular HtrA1 activity and inhibition using novel activity based probe
Author Affiliations & Notes
  • Irene Tom
    OMNI Biomarker Development, Genentech, South San Francisco, California, United States
  • Johnny Gutierrez
    OMNI Biomarker Development, Genentech, South San Francisco, California, United States
  • Kenneth J Katschke
    Immunology, Genentech, South San Francisco, California, United States
  • Isabel Figueroa
    PTPK, Genentech, South San Francisco, California, United States
  • Victoria Pham
    Microchemistry, Proteomics & Lipidomics, Genentech, South San Francisco, California, United States
  • Helen S Booler
    Safety Assessment, Genentech, South San Francisco, California, United States
  • Linda Rangell
    Pathology, Genentech, South San Francisco, California, United States
  • Sheila Ulufatu
    DevSci SA gNO, Genentech, South San Francisco, California, United States
  • Guy Salvesen
    Medical discovery institute, Sanford Burnham Prebys, La Jolla, California, United States
  • Jennie Lill
    Microchemistry, Proteomics & Lipidomics, Genentech, South San Francisco, California, United States
  • Menno Van Lookeren Campagne
    Immunology, Genentech, South San Francisco, California, United States
  • Amos Baruch
    OMNI Biomarker Development, Genentech, South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Irene Tom, Genentech (E); Johnny Gutierrez, Genentech (E); Kenneth Katschke, Genentech (E); Isabel Figueroa, Genentech (E); Victoria Pham, Genentech (E); Helen Booler, Genentech (E); Linda Rangell, Genentech (E); Sheila Ulufatu, Genentech (E); Guy Salvesen, Genentech (C); Jennie Lill, Genentech (E); Menno Van Lookeren Campagne, Genentech (E); Amos Baruch, Genentech (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2441. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Irene Tom, Johnny Gutierrez, Kenneth J Katschke, Isabel Figueroa, Victoria Pham, Helen S Booler, Linda Rangell, Sheila Ulufatu, Guy Salvesen, Jennie Lill, Menno Van Lookeren Campagne, Amos Baruch; Determining ocular HtrA1 activity and inhibition using novel activity based probe. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2441.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : HtrA1 is a serine protease expressed in the eye and implicated, through genome-wide association studies, in age-related macular degeneration (AMD). Since the endogenous substrates of HtrA1 are unknown, it is challenging to determine its activity within the eye. Here, we report the design and characterization of a HtrA1 activity-based probe (ABP) that specifically binds to the active form of HtrA1.

Methods : A specific HtrA1 ABP was developed and characterized in vitro and in vivo. To determine HtrA1 activity in the retina, HtrA1 ABP was administered to Dutch-Belted rabbit eyes via intravitreal (ITV) injection at a dose of 10uM/eye and retinas were subjected to immunohistochemical analysis. Pharmacodynamic (PD) analysis using the HtrA1 ABP was performed on vitreous humor from rabbits that were treated with Anti-HtrA1 mAb or control by bilateral ITV injection dosing.

Results : In vitro, the HtrA1 ABP covalently modified recombinant WT HtrA1 but did not bind a mutated S328A inactive enzyme. Furthermore, ABP-labeling of recombinant HtrA1 was blocked in the presence of Anti-HtrA1 mAb inhibitor (Anti-HtrA1). Using the ABP we were able to detect HtrA1 activity directly in rabbit vitreous but not in aqueous humor. Moreover, direct administration of the ABP intravitreally confirmed activity of HtrA1 in vivo. We next used the HtrA1 ABP as a PD tool to determine HtrA1 inhibition in vitreous humor from rabbits administered with anti-HtrA1. HtrA1 activity was detected in controls but was markedly inhibited in a dose-related manner following IVT injection of Anti-HtrA1.

Conclusions : This activity-based approach provides information on the spatial and temporal patterns of HtrA1 activity within its natural environment and can further shed light on its role in AMD disease initiation and progression.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×